Frontlight ResearchEarly access
Taking peopleNo phase
Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)
Key facts
- Who runs it
- Hangzhou Endonom Medtech Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 216 people, planned
- Started
- 13 Jul 2026
- Expected to end
- Oct 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- WeFlow-EndoPatch Aortic Endovascular Patch System
- Conventional Treatment group
- Record updated
- 26 August 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients aged 18 to 80 years old, no gender limitation
- The patient was diagnosed with chronic aortic dissection after the repair of the main artery dissection, with distal tears required seal
- The maximum diameter of the descending thoracic aorta is 3.5-5cm;
- The number of thoracic descending aorta tears is ≤2, and the maximum diameter of the tears is 2-30 mm;
- With appropriate artery approaches, endovascular treatment can be performed;
- Those who can understand the purpose of the trial, voluntarily participate in the study, sign the informed consent form by themselves or their legal representative, and are willing to complete the follow-up according to the protocol requirements
Who cannot take part
- Participated in clinical trials of other drugs or devices during the same period
- The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.)
- Acute systemic infection
- History of myocardial infarction, TIA or cerebral infarction within the past 3 months
- Allergic to contrast agents, anesthetics, patchs, and delivery materials
- Life expectancy is less than 12 months (such as advanced malignant tumors); Investigator judged that not suitable for interventional treatment
- Cardiac function Grade IV (NYHA rating) or LVEF \< 30%
- Hematological abnormalities: leukopenia (WBC \< 3×10\^9/L), anemia (Hb \< 90 g/L); Coagulation dysfunction, thrombocytopenia (PLT count \< 50×10\^9/L)
- Renal insufficiency: serum creatinine \> 150 umol/L (or 3.0 mg/dL) and/or advanced kidney disease requiring renal dialysis, as determined by the investigator after thorough analysis
- Severe liver insufficiency: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds the normal upper limit by 5 times; Serum total bilirubin (STB) exceeded the normal upper limit by 2 times
- Rupture or threatened rupture of aortic dissection
- Proximal type I internal leakage after aortic repair
- New distal SINE
- Abdominal aortic dissection aneurysm diameter ≥5 cm
- The edge of the tear from the opening of celiac trunk is<4 mm
- Pregnant or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)
The 2 groups in the trial
- EndoPatch GroupTreatment being tested
Subject in this group will receive treatment with the WeFlow-EndoPatch Aortic Endovascular Patch System.
Treatment: WeFlow-EndoPatch Aortic Endovascular Patch System
- Control GroupOther group
Subject in this group will receive conventional treatment.
Treatment: Conventional Treatment group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Guo&Amp;'s Distal Entry Tear Repair: a Multicenter, Prospective, Superiority, Randomized Controlled Trial of the Novel WeFlow-EndoPatch Aortic Endovascular Patch System
- Fit questions
- Built from NCT06945809, who can take part
- Record updated
- 26 August 2026